SAM
URGN icon

Sectoral Asset Management’s UroGen Pharma URGN Stock Holding History

Sectoral Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-65,063
Closed -$1.55M – 69
2019
Q3 		$1.55M Hold
65,063
– – 0.27% 55
2019
Q2 		$2.34M Hold
65,063
– – 0.28% 61
2019
Q1 		$2.4M Buy
+65,063
New +$2.73M 0.29% 67

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sectoral Asset Management's URGN Position: Q4 2019 in Review

Sectoral Asset Management sold out of UroGen Pharma (URGN) in Q4 2019, closing a stake of 65,063 shares — an estimated $1.55M sold.

Sectoral Asset Management first reported a position in URGN in Q1 2019 and held it in 3 quarters. The position peaked at $2.4M in Q1 2019. 86 funds tracked by Wall St. Rank hold URGN as of Q4 2019.

  • Sectoral Asset Management reported no remaining UroGen Pharma position as of Q4 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 65,063 UroGen Pharma shares in Q4 2019, an estimated $1.55M.
  • Sectoral Asset Management first reported a position in UroGen Pharma in Q1 2019 and held it in 3 quarters.
  • Sectoral Asset Management's UroGen Pharma position peaked at $2.4M in Q1 2019.
  • 86 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2019.

Based on Sectoral Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.